Market revenue in 2020 | USD 1,318.6 million |
Market revenue in 2028 | USD 2,328.5 million |
Growth rate | 7.4% (CAGR from 2020 to 2028) |
Largest segment | Laboratory technologies |
Fastest growing segment | Online Technologies |
Historical data | 2020 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Laboratory Technologies, Online Technologies |
Key market players worldwide | Thermo Fisher Scientific Inc, Pfizer Inc, Sartorius AG, Stemcell Holdings Inc Ordinary Shares, Illumina Inc, Agilent Technologies Inc, Bio-Rad Laboratories Inc, Danaher Corp, Merck KGaA, Qiagen NV, Shimadzu Corp, Eurofins Scientific SE, Charles River Laboratories International Inc, Takara Bio Inc, Olympus Corp, Avantor Inc, Aurora Innovation Inc Class A, Standard BioTools Inc, Celerion, Cole-Parmer, Hartford Schroders International Stk I, Revvity Inc, Fluidigm Corporation, Polyplus-transfection, Hamilton Lane Inc Class A |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to covid-19 vaccine development tools market will help companies and investors design strategic landscapes.
Laboratory technologies was the largest segment with a revenue share of 95.12% in 2020. Horizon Databook has segmented the Germany covid-19 vaccine development tools market based on laboratory technologies, online technologies covering the revenue growth of each sub-segment from 2020 to 2028.
Government funding for R&D and strategic initiatives by key players are among key growth determinants for COVID-19 vaccine development tools market in Germany. For instance, Biotech collaborated with a U.S.-based pharma company to develop an mRNA vaccine and the company received USD 445 million from Berlin regulatory to support domestic manufacturing & development of the vaccine.
Similarly, in September 2020, Biotech acquired a GMP manufacturing site in Germany to build an additional vaccine production capacity of 60 million doses per month. Cueva, one of the key players in the region, partnered with GSK to develop an mRNA-based COVID-19 vaccine.
Moreover, the central government invested a significant amount to increase research and production of COVID-19 vaccines. For instance, in June 2020, the government bought equity worth USD 340 million in CureVac.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany covid-19 vaccine development tools market , including forecasts for subscribers. This country databook contains high-level insights into Germany covid-19 vaccine development tools market from 2020 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account